Clover Health exec sells 1,921 shares at $4.56

Clover Health’s Medicare Advantage CEO reported a small Rule 10b5-1 plan sale, retaining over 2.8 million shares.

Available on EDGAR 09/18/2026 - 04:23 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) executive Jamie L. Reynoso, CEO, Medicare Advantage, reported a sale of 1,921 shares of Class A Common Stock on September 17, 2026 at $4.56 per share in an open-market or private transaction, leaving 2,803,446 shares held directly. The sale was effected under a Rule 10b5-1 trading plan adopted on March 12, 2026.

Insider Trade Summary 10b5-1

Net Seller: 1,921 shares

Net Sell 1 txn

Insider Reynoso Jamie L.

Role CEO, Medicare Advantage

Sold 1,921 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	1,921	$4.56	$9K

Holdings After Transaction: Class A Common Stock — 2,803,446 shares (Direct)

Footnotes (1)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.

Key Figures

Shares sold: 1,921 shares Sale price per share: $4.56 per share Shares held after transaction: 2,803,446 shares +1 more

4 metrics

Shares sold 1,921 shares Class A Common Stock sold by Jamie L. Reynoso on September 17, 2026

Sale price per share $4.56 per share Price for the Class A Common Stock sale on September 17, 2026

Shares held after transaction 2,803,446 shares Direct holdings of Jamie L. Reynoso following the reported sale

Adoption date of Rule 10b5-1 plan March 12, 2026 Trading plan under which the September 17, 2026 sale was effected

Key Terms

Rule 10b5-1 trading plan, Class A Common Stock, open-market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported ... was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Class A Common Stock financial

"reported a sale of Class A Common Stock on September 17, 2026"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open-market or private transaction financial

"Sale in an open-market or private transaction on September 17, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CLOV report for Jamie L. Reynoso?

Jamie L. Reynoso reported selling 1,921 shares of Clover Health Class A Common Stock on September 17, 2026 in an open-market or private transaction at $4.56 per share, according to the Form 4.

How many CLOV shares does Jamie L. Reynoso hold after the reported sale?

After the reported sale, Jamie L. Reynoso directly holds 2,803,446 shares of Clover Health Class A Common Stock, as stated in the Form 4 filing.

Was the CLOV insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Jamie L. Reynoso on March 12, 2026, meaning the trades were pre-arranged under that plan.

What price did Jamie L. Reynoso receive per CLOV share in the sale?

The reported sale of Clover Health Class A Common Stock was executed at $4.56 per share on September 17, 2026, based on the Form 4 disclosure.

What is Jamie L. Reynoso’s role at CLOV mentioned in the Form 4?

Jamie L. Reynoso is identified as CEO, Medicare Advantage at Clover Health Investments, Corp., serving as an officer of the company in that capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynoso Jamie L.

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Medicare Advantage

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/17/2026		S		1,921(1)	D	$4.56	2,803,446	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)